Loading...
•
Sep 30, 2023
Xeris Biopharma Q3 2023 Earnings Report
Achieved record revenue with a significant increase from the prior year and prior quarter, while tightening full-year revenue guidance and maintaining focus on cash flow breakeven.
Key Takeaways
Xeris Biopharma reported record revenue of $48.3 million for the third quarter of 2023, a 27% increase from the previous quarter and a 63% increase from the same period last year. The company has tightened its full-year 2023 revenue guidance to $160 million - $165 million and is on track to achieve cash flow breakeven in the fourth quarter.
Record revenue of $48.3 million, a 27% increase from prior quarter and a 63% increase from the same period prior year.
Tightened full-year 2023 revenue guidance from $155 million-$165 million to $160 million-$165 million.
Ended Q3 with $66.0 million in cash, cash equivalents and short-term investments.
Remains on track to achieve cash flow breakeven in the fourth quarter.
Revenue by Segment
Forward Guidance
The company has tightened its full-year 2023 revenue guidance to $160 million - $165 million and is on track to achieve cash flow breakeven in the fourth quarter.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...